Genomic alterations and evolution in patients with prostate cancer with histologic evidence of neuroendocrine differentiation.
Barnett E, Carbone E, Keegan N, Vasselman S, Nweji B, Zaidi S, Scher H. Genomic alterations and evolution in patients with prostate cancer with histologic evidence of neuroendocrine differentiation. Journal Of Clinical Oncology 2022, 40: 5029-5029. DOI: 10.1200/jco.2022.40.16_suppl.5029.Peer-Reviewed Original ResearchCastration resistant prostate cancerCastrate resistant prostate cancer samplesNeuroendocrine prostate cancerHistological transformationRB1 alterationsProstate cancerDevelopment of neuroendocrine prostate cancerInhibits androgen receptor signalingNeuroendocrine prostate cancer patientsConfidence intervalsEvidence of neuroendocrine differentiationResistant prostate cancerProstate cancer patientsAndrogen receptor signalingIRB-approved protocolFOXA1 mutationsSequencing resultsTP53 alterationsAR alterationsNeuroendocrine differentiationMSK-IMPACTDifferentially altered genesPathology reportsPanel sequencingDisease course
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply